Participants with worse clinical impairment compared with biological impairment often presented with other pathologies, such as α-synuclein positivity, higher NfL levels, advanced TDP-43-like ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

People whose cognitive symptoms were more severe than their biological Alzheimer's stage often had additional pathologies. Alpha-synuclein, TDP-43 signatures, and cerebral small vessel disease were ...

A team of researchers at the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained through a simple blood test, can predict the clinical progression ...

Scientists from Johns Hopkins Medicine report new evidence that clusters of brain tissue derived from the cells of patients with Alzheimer’s disease may be used to evaluate how ...